Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Discrimination between benign and malignant prostate biopsies using three-dimensional chromatin texture analysis by confocal laser scanning microscopy.

Huisman A, Ploeger LS, Dullens HF, Jonges TN, van Diest PJ.

Anal Quant Cytol Histol. 2011 Oct;33(5):265-70.

PMID:
22611753
2.

Integrin expression during reverse remodeling in the myocardium of heart failure patients.

Dullens HF, Schipper ME, van Kuik J, Sohns W, Scheenstra M, van Wichen DF, Van Oosterhout MF, de Jonge N, de Weger RA.

Cardiovasc Pathol. 2012 Jul-Aug;21(4):291-8. doi: 10.1016/j.carpath.2011.09.009. Epub 2011 Nov 18.

3.

Osteopontin: a potential biomarker for heart failure and reverse remodeling after left ventricular assist device support.

Schipper ME, Scheenstra MR, van Kuik J, van Wichen DF, van der Weide P, Dullens HF, Lahpor J, de Jonge N, De Weger RA.

J Heart Lung Transplant. 2011 Jul;30(7):805-10. doi: 10.1016/j.healun.2011.03.015. Epub 2011 May 4.

PMID:
21531579
4.

Changes in regulatory microRNA expression in myocardium of heart failure patients on left ventricular assist device support.

Schipper ME, van Kuik J, de Jonge N, Dullens HF, de Weger RA.

J Heart Lung Transplant. 2008 Dec;27(12):1282-5. doi: 10.1016/j.healun.2008.09.005.

PMID:
19059107
5.

Fluorescent stains for quantification of DNA by confocal laser scanning microscopy in 3-D.

Ploeger LS, Dullens HF, Huisman A, van Diest PJ.

Biotech Histochem. 2008 Apr;83(2):63-9. doi: 10.1080/10520290802127586. Review.

PMID:
18568680
6.

Long-term toxicity of holmium-loaded poly(L-lactic acid) microspheres in rats.

Zielhuis SW, Nijsen JF, Seppenwoolde JH, Bakker CJ, Krijger GC, Dullens HF, Zonnenberg BA, van Rijk PP, Hennink WE, van het Schip AD.

Biomaterials. 2007 Nov;28(31):4591-9. Epub 2007 Jul 25.

PMID:
17655925
7.

A restaining method to restore faded fluorescence in tissue specimens for quantitative confocal microscopy.

Huisman A, Ploeger LS, Dullens HF, Beekhuis JT, van Diest PJ.

Cytometry A. 2007 Oct;71(10):875-81.

8.

Discrimination between benign and malignant prostate tissue using chromatin texture analysis in 3-D by confocal laser scanning microscopy.

Huisman A, Ploeger LS, Dullens HF, Jonges TN, Belien JA, Meijer GA, Poulin N, Grizzle WE, van Diest PJ.

Prostate. 2007 Feb 15;67(3):248-54.

PMID:
17075809
9.

Development of 3D chromatin texture analysis using confocal laser scanning microscopy.

Huisman A, Ploeger LS, Dullens HF, Poulin N, Grizzle WE, van Diest PJ.

Cell Oncol. 2005;27(5-6):335-45.

10.

Implementation of accurate and fast DNA cytometry by confocal microscopy in 3D.

Ploeger LS, Huisman A, van der Gugten J, van der Giezen DM, Beliën JA, Abbaker AY, Dullens HF, Grizzle W, Poulin NM, Meijer GA, van Diest PJ.

Cell Oncol. 2005;27(4):225-30.

11.

Intra-arterial embolization of head-and-neck cancer with radioactive holmium-166 poly(L-lactic acid) microspheres: an experimental study in rabbits.

van Es RJ, Nijsen JF, van het Schip AD, Dullens HF, Slootweg PJ, Koole R.

Int J Oral Maxillofac Surg. 2001 Oct;30(5):407-13.

PMID:
11720043
12.

Tumour embolization of the Vx2 rabbit head and neck cancer model with Dextran hydrogel and Holmium-poly(L-lactic acid) microspheres: a radionuclide and histological pilot study.

van Es RJ, Nijsen JF, Dullens HF, Kicken M, van der Bilt A, Hennink W, Koole R, Slootweg PJ.

J Craniomaxillofac Surg. 2001 Oct;29(5):289-97.

PMID:
11673924
13.

Evaluation of the VX2 rabbit auricle carcinoma as a model for head and neck cancer in humans.

van Es RJ, Dullens HF, van der Bilt A, Koole R, Slootweg PJ.

J Craniomaxillofac Surg. 2000 Oct;28(5):300-7.

PMID:
11467394
14.

Influence of p53 and bcl-2 on proliferative activity and treatment outcome in head and neck cancer patients.

Dijkema IM, Struikmans H, Dullens HF, Kal HB, van der Tweel I, Battermann JJ.

Oral Oncol. 2000 Jan;36(1):54-60.

PMID:
10889920
15.

The VX2 carcinoma in the rabbit auricle as an experimental model for intra-arterial embolization of head and neck squamous cell carcinoma with dextran microspheres.

van Es RJ, Franssen O, Dullens HF, Bernsen MR, Bosman F, Hennink WE, Slootweg PJ.

Lab Anim. 1999 Apr;33(2):175-84.

PMID:
10780822
16.

Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.

Struikmans H, Rutgers DH, Jansen GH, Dullens HF, Oosten L, Tulleken CA, van der Tweel I, Battermann JJ.

Radiat Oncol Investig. 1999;7(4):243-8.

PMID:
10492165
17.

Interleukin-2: hope in cases of cisplatin-resistant tumours.

Bernsen MR, Van Der Velden AW, Everse LA, Dullens HF, Den Otter W, Heintz AP.

Cancer Immunol Immunother. 1998 Mar;46(1):41-7.

PMID:
9520291
18.

Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study.

Everse LA, Renes IB, Jürgenliemk-Schulz IM, Rutgers DH, Bernsen MR, Dullens HF, Den Otter W, Battermann JJ.

Int J Cancer. 1997 Sep 17;72(6):1003-7.

19.

Priming of the antitumor response promotes efficacy of interleukin-2 therapy.

Everse LA, Bernsen MR, Dullens HF, Den Otter W.

Cancer Immunol Immunother. 1997 Jun;44(4):221-9.

PMID:
9222281
20.

Membrane modifications in human erythroleukemia K562 cells during induction of programmed cell death by transforming growth factor beta 1 or cisplatin.

Maccarrone M, Nieuwenhuizen WE, Dullens HF, Catani MV, Melino G, Veldink GA, Vliegenthart JF, Finazzo Agrò A.

Eur J Biochem. 1996 Oct 1;241(1):297-302.

21.
22.

The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.

Voshol H, Dullens HF, Den Otter W, Vliegenthart JF.

Anticancer Res. 1996 Jan-Feb;16(1):155-9.

PMID:
8615602
23.

Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.

Bernsen MR, Dullens HF, Den Otter W, Heintz PM.

J Interferon Cytokine Res. 1995 Jul;15(7):641-5.

PMID:
7553236
24.

Effect of immunomodulators on specific tumor immunity induced by liposome-encapsulated tumor-associated antigens.

Bergers JJ, Den Otter W, Dullens HF, De Groot JW, Steerenberg PA, Filius PM, Crommelin DJ.

Int J Cancer. 1994 Mar 1;56(5):721-6.

PMID:
8314349
25.

Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines.

Bergers JJ, Den Otter W, Dullens HF, Kerkvliet CT, Crommelin DJ.

Pharm Res. 1993 Dec;10(12):1715-21.

PMID:
8302756
26.

Human natural killer cells: a convenient purification procedure and the influence of cryopreservation on cytotoxic activity.

Voshol H, Dullens HF, Den Otter W, Vliegenthart JF.

J Immunol Methods. 1993 Sep 27;165(1):21-30.

PMID:
8409465
27.

Critical factors for liposome-incorporated tumour-associated antigens to induce protective tumour immunity to SL2 lymphoma cells in mice.

Bergers JJ, Den Otter W, Dullens HF, De Groot JW, Steerenberg PA, Mimpen MW, Crommelin DJ.

Cancer Immunol Immunother. 1993 Sep;37(4):271-9.

PMID:
8348566
28.

Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice.

Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HF, Den Otter WD.

Immunobiology. 1993 Jul;188(3):281-92.

PMID:
7901148
29.

Dualistic effects of cis-diammine-dichloro-platinum on the anti-tumor efficacy of subsequently applied recombinant interleukin-2 therapy: a tumor-dependent phenomenon.

Bernsen MR, Van Barlingen HJ, Van der Velden AW, Dullens HF, Den Otter W, Heintz AP.

Int J Cancer. 1993 May 28;54(3):513-7.

PMID:
8509227
31.

Interleukin-2 in cancer treatment: disappointing or (still) promising? A review.

Maas RA, Dullens HF, Den Otter W.

Cancer Immunol Immunother. 1993;36(3):141-8. Review.

PMID:
8439974
32.

Histological analysis of IL-2 induced regression of murine solid SL2-tumors.

Maas RA, Dullens HF, Henk D, Van Weering J, De Mik HJ, Koten JW, Belger RJ, Den Otter W.

Biotherapy. 1993;6(2):83-91.

PMID:
8104452
33.

Involvement of the omental lymphoid organ in the induction of peritoneal immunity against tumor cells.

Dullens HF, Rademakers LH, Doffemont M, Van Veen PT, Bulder R, Den Otter W.

Invasion Metastasis. 1993;13(5):267-76.

PMID:
7960579
34.

Effector cells of low-dose IL-2 immunotherapy in tumor bearing mice: tumor cell killing by CD8+ cytotoxic T lymphocytes and macrophages.

Maas RA, Roest PA, Becker MJ, Weimar IS, Dullens HF, Den Otter W.

Immunobiology. 1992 Nov;186(3-4):214-29.

PMID:
1490728
35.

T cells and tumors.

Maas RA, Dullens HF, Den Otter W.

Immunol Today. 1992 Feb;13(2):78-9. No abstract available.

PMID:
1575895
36.

Reconstituted membranes of tumour cells (proteoliposomes) induce specific protection to murine lymphoma cells.

Bergers JJ, Den Otter W, De Groot JW, De Blois AW, Dullens HF, Steerenberg PA, Crommelin DJ.

Cancer Immunol Immunother. 1992;34(4):233-40.

PMID:
1537056
37.

Tumour regression by IL-2 mediated stagnation of blood flow.

De Mik HJ, Koten JW, Maas RA, Dullens HF, Den Otter W.

In Vivo. 1991 Nov-Dec;5(6):679-84.

PMID:
1810455
38.

Mechanisms of tumor regression induced by low doses of interleukin-2.

Maas RA, Dullens HF, Den Otter W.

In Vivo. 1991 Nov-Dec;5(6):637-41.

PMID:
1810449
39.

Cancer treatment with interleukins 1, 4 and 6 and combinations of cytokines: a review.

Dullens HF, De Wit CL.

In Vivo. 1991 Nov-Dec;5(6):567-70. Review.

PMID:
1810440
40.

Effective immunotherapy with local low doses of interleukin-2.

Den Otter W, Maas RA, Koten JW, Dullens HF, Bernsen M, Klein WR, Rutten VP, Steerenberg PA, Balemans L, Ruitenberg EJ, et al.

In Vivo. 1991 Nov-Dec;5(6):561-5. Review.

PMID:
1810439
41.

Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.

Dullens HF, Wind JC, Maas RA, Bernsen MR, Vulto IM, Rademakers LH, Den Otter W.

Int Immunol. 1991 Oct;3(10):959-64.

PMID:
1756146
42.

Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour.

Maas RA, Van Weering DH, Dullens HF, Den Otter W.

Cancer Immunol Immunother. 1991;33(6):389-94.

PMID:
1908746
43.

Parathymic lymph nodes during growth and rejection of intraperitoneally inoculated tumor cells.

Dullens HF, Rademakers LH, Cluistra S, Van Os R, Dux K, Den Besten PJ, Den Otter W.

Invasion Metastasis. 1991;11(4):216-26.

PMID:
1765434
44.
45.

Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system.

Characiejus D, Dullens HF, Den Otter W.

Cancer Immunol Immunother. 1990;32(3):179-84.

PMID:
2289212
46.

Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.

Maas RA, Dullens HF, De Jong WH, Den Otter W.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7037-40.

47.

Production of specific macrophage-arming factor precedes cytotoxic T lymphocyte activity in vivo during tumor rejection.

Dullens HF, De Weger RA, Van der Maas M, Den Besten PJ, Vandebriel RJ, Den Otter W.

Cancer Immunol Immunother. 1989;30(1):28-33.

PMID:
2598173
48.

Initial immunochemical characterization of specific macrophage-arming factor.

De Weger RA, Vandebriel RJ, Slager H, Mans D, Van Loveren H, Wilbrink B, Dullens HF, Den Otter W.

Cancer Immunol Immunother. 1989;30(1):21-7.

PMID:
2598172
49.

Lack of correlation between in vivo peroxidatic activity patterns and tumoricidal activity in vitro of peritoneal macrophages after intraperitoneal immunization with tumor cells.

Dullens HF, van Walraven R, Klomberg M, Rademakers LP, de Goey IC, den Otter W.

Immunobiology. 1988 Jul;177(3):293-304.

PMID:
3169842
50.

Spontaneous tumor rejection is not always due to a complete cellular rejection.

Dullens HF, Schakenrad S, Den Otter W.

Exp Pathol. 1987;31(1):33-8.

PMID:
3569480

Supplemental Content

Loading ...
Support Center